ArticleEBioMedicine2016
Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast Cancer.
Article in EBioMedicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Diagnostic and Prognostic Value of miR-200c in Gastric Cancer: A Meta-Analysis.Disease markers · 2019Pooled it
- MicroRNAs and their role in breast cancer metabolism (Review).International journal of oncology · 2025Review
- Functions and applications of RNA interference and small regulatory RNAs.Acta biochimica et biophysica Sinica · 2024Review
- Unraveling the Potential of miRNAs from CSCs as an Emerging Clinical Tool for Breast Cancer Diagnosis and Prognosis.International journal of molecular sciences · 2023Review
- A 10-miRNA risk score-based prediction model for pathological complete response to neoadjuvant chemotherapy in hormone receptor-positive breast cancer.Science China. Life sciences · 2022Article
- Noncoding RNome as Enabling Biomarkers for Precision Health.International journal of molecular sciences · 2022Review
- Review
- SETD1A-SOX2 axis is involved in tamoxifen resistance in estrogen receptor α-positive breast cancer cells.Theranostics · 2022Article
- MiR-139 Modulates Cancer Stem Cell Function of Human Breast Cancer through Targeting CXCR4.Cancers · 2021Article
- Development of a prognostic signature for bladder cancer based on immune-related genes.Annals of translational medicine · 2020Article
- Autophagy-associated circRNA circCDYL augments autophagy and promotes breast cancer progression.Molecular cancer · 2020Article
- Five microRNAs in Serum Are Able to Differentiate Breast Cancer Patients From Healthy Individuals.Frontiers in oncology · 2020Article
- Circulating non‑coding RNA‑biomarker potential in neoadjuvant chemotherapy of triple negative breast cancer?International journal of oncology · 2020Article
- Prognostic role of microRNAs in breast cancer: A systematic review.Oncotarget · 2019Article
- Article
- Metformin mediates induction of miR-708 to inhibit self-renewal and chemoresistance of breast cancer stem cells through targeting CD47.Journal of cellular and molecular medicine · 2019Article
- The targeting of non‑coding RNAs by curcumin: Facts and hopes for cancer therapy (Review).Oncology reports · 2019Review
- Identification of a 4-mRNA metastasis-related prognostic signature for patients with breast cancer.Journal of cellular and molecular medicine · 2019Article
- Article
- Human Mitotic Centromere-Associated Kinesin Is Targeted by MicroRNA 485-5p/181c and Prognosticates Poor Survivability of Breast Cancer.Journal of oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeBreast cancer patients with high proportion of cancer stem cells (BCSCs) have unfavorable clinical outcomes. MicroRNAs (miRNAs) regulate key features of BCSCs. We hypothesized that a biology-driven model based on BCSC-associated miRNAs could predict prognosis for the most common subtype, hormone receptor (HR)-positive, HER2-negative breast cancer patients. PATIENTS AND
methodsAfter screening candidate miRNAs based on literature review and a pilot study, we built a miRNA-based classifier using LASSO Cox regression method in the training group (n=202) and validated its prognostic accuracy in an internal (n=101) and two external validation groups (n=308).
resultsIn this multicenter study, a 10-miRNA classifier incorporating miR-21, miR-30c, miR-181a, miR-181c, miR-125b, miR-7, miR-200a, miR-135b, miR-22 and miR-200c was developed to predict distant relapse free survival (DRFS). With this classifier, HR+HER2- patients were scored and classified into high-risk and low-risk disease recurrence, which was significantly associated with 5-year DRFS of the patients. Moreover, this classifier outperformed traditional clinicopathological risk factors, IHC4 scoring and 21-gene Recurrence Score (RS). The patients with high-risk recurrence determined by this classifier benefit more from chemotherapy.
conclusionsOur 10-miRNA-based classifier provides a reliable prognostic model for disease recurrence in HR+HER2- breast cancer patients. This model may facilitate personalized therapy-decision making for HR+HER2- individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.